Photo of Jin  Han

Jin Han

Clinical Pharmacist, Ambulatory Pharmacy Services
Clinical Assistant Professor, Pharmacy Practice
Center Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research


Building & Room:

CSB Rm 340


833 S. Wood Street Rm 164 (MC886), Chicago, IL, 60612

Office Phone:

(312) 355-1213


Dr. Han is a clinical assistant professor in the Department of Pharmacy Practice, and a clinical pharmacist in the UIH Comprehensive Sickle Cell Center. His areas of interest and research include pain management, sickle cell disease (SCD), safety and effectiveness of agents used in SCD, evaluation of clinical pharmacy services and interventions, and pharmacogenomics.

Selected Publications

  • Zhou J, Han J, Nutescu EA, Galanter WL, Walton SM, Gordeuk VR, Saraf SL, Calip GS. Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis.. British journal of haematology. 2019;185(1):116-127. doi:10.1111/bjh.15773.
  • Viner M, Zhou J, Allison D, Han J, Molokie RE, Jain S, Gowhari M, Gordeuk VR, Calip GS, Saraf SL. The morbidity and mortality of end stage renal disease in sickle cell disease.. American journal of hematology. 2019;. doi:10.1002/ajh.25439.
  • Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR. “Maximum Tolerated Dose” versus “Fixed Low-Dose” Hydroxyurea for Treatment of Adults with Sickle Cell Anemia.. American journal of hematology. 2019;. doi:10.1002/ajh.25412.
  • Zhou J, Han J, Nutescu EA, Patel PR, Sweiss KI, Calip GS. Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study.. Pharmacotherapy. 2019;39(1):55-66. doi:10.1002/phar.2197.
  • Han J, Saraf SL, Gowhari M, Jain S, Molokie RE, Gordeuk VR. High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.. American journal of hematology. 2019;94(1):E5-E7. doi:10.1002/ajh.25311.
  • Han J, Saraf SL, Molokie RE, Gordeuk VR. Use of metformin in patients with sickle cell disease.. American journal of hematology. 2019;94(1):E13-E15. doi:10.1002/ajh.25313.
  • Raslan R, Shah BN, Zhang X, Kanias T, Han J, Machado RF, Gladwin MT, Gordeuk VR, Saraf SL. Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease.. American journal of hematology. 2018;93(11):E376-E380. doi:10.1002/ajh.25258.
  • Saraf SL, Viner M, Rischall A, Raslan R, Shah BN, Zhang X, Han J, Gowhari M, Jain S, Molokie RE, Machado RF, Lash JP, Gordeuk VR. HMOX1 and acute kidney injury in sickle cell anemia.. Blood. 2018;132(15):1621-1625. doi:10.1182/blood-2018-05-853929.
  • Han J, Zhou J, Kondragunta V, Zhang X, Molokie RE, Gowhari M, Hassan J, Jain S, Calip GS, Gordeuk VR, Saraf SL. Erythropoiesis-stimulating agents in sickle cell anaemia.. British journal of haematology. 2018;182(4):602-605. doi:10.1111/bjh.14846.
  • Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.. British journal of haematology. 2018;182(2):259-270. doi:10.1111/bjh.15396.
  • Han J, Zhang X, Saraf SL, Gowhari M, Molokie RE, Hassan J, Jain S, Shah BN, Abbasi T, Machado RF, Gordeuk VR. Risk factors for vitamin D deficiency in sickle cell disease.. British journal of haematology. 2018;181(6):828-835. doi:10.1111/bjh.15270.
  • Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease.. Pharmacoepidemiology and drug safety. 2018;27(5):479-486. doi:10.1002/pds.4291.
  • Han J, Saraf SL, Kavoliunaite L, Jain S, Hassan J, Hsu LL, Molokie RE, Gordeuk VR, Gowhari M. Program expansion of a day hospital dedicated to manage sickle cell pain.. American journal of hematology. 2018;93(1):E20-E21. doi:10.1002/ajh.24938.
  • Han J, Saraf SL, Lash JP, Gordeuk VR. Use of anti-inflammatory analgesics in sickle-cell disease.. Journal of clinical pharmacy and therapeutics. 2017;42(5):656-660. doi:10.1111/jcpt.12592.
  • Han J, Zhang X, Oderinde J, Saraf SL, Gowhari M, Hassan J, Jain S, Gordeuk VR, Molokie RE. Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways.. Haematologica. 2017;102(8):e282-e284. doi:10.3324/haematol.2017.169128.
  • Bhat S, Han J. Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease. Annals of Pharmacotherapy. 2017;51(4):357-358. doi:10.1177/1060028016681129.
  • Han J, Saraf SL, Machado RF, Gordeuk VR. Reply to Ruan X et al: “A comment on pattern of opioid use in sickle cell disease”.. American journal of hematology. 2017;92(4):E43. doi:10.1002/ajh.24646.
  • Saraf SL, Shah BN, Zhang X, Han J, Tayo BO, Abbasi T, Ostrower A, Guzman E, Molokie RE, Gowhari M, Hassan J, Jain S, Cooper RS, Machado RF, Lash JP, Gordeuk VR. APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia.. Haematologica. 2017;102(1):e1-e6. doi:10.3324/haematol.2016.154153.
  • Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center.. Pharmacotherapy. 2016;36(11):1166-1172. doi:10.1002/phar.1834.
  • Han J, Saraf SL, Zhang X, Gowhari M, Molokie RE, Hassan J, Alhandalous C, Jain S, Younge JS, Abbasi T, Machado RF, Gordeuk VR. Patterns of opioid use in sickle cell disease.. American journal of hematology. 2016;91(11):1102-1106. doi:10.1002/ajh.24498.
  • Han J, Saraf SL, Gordeuk VR, Gowhari M. Safety of chronic transdermal fentanyl use in patients receiving hemodialysis.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016;73(13):947-8. doi:10.2146/ajhp150748.
  • Rosenberg A, Selounski V, Wardak H, Han J, Gowhari M, Hassan J, Jain S, Molokie RE, Gordeuk VR, Saraf SL. Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sβ+-thalassemia sickle cell disease.. American journal of hematology. 2016;91(6):E316-7. doi:10.1002/ajh.24363.
  • Alhandalous CH, Han J, Hsu L, Gowhari M, Hassan J, Molokie R, Abbasi TA, Gordeuk VR. Platelets decline during Vaso-occlusive crisis as a predictor of acute chest syndrome in sickle cell disease.. American journal of hematology. 2015;90(12):E228-9. doi:10.1002/ajh.24214.
  • Zhang X, Zhang W, Saraf SL, Nouraie M, Han J, Gowhari M, Hassan J, Miasnikova G, Sergueeva A, Nekhai S, Kittles R, Machado RF, Garcia JG, Gladwin MT, Steinberg MH, Sebastiani P, McClain DA, Gordeuk VR. Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease.. Human genetics. 2015;134(8):895-904. doi:10.1007/s00439-015-1572-3.
  • Han J, Kemiki O, Hsu LL, Rivers AE. Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease.. Pharmacotherapy. 2015;35(7):696-700. doi:10.1002/phar.1607.
  • Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo VL, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH. Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One. 2013;8(7):e71268. doi:10.1371/journal.pone.0071268.
  • Ye Z, Palazzo JP, Lin L, Lai Y, Guiles F, Myers RE, Han J, Xing J, Yang H. Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. J Gastroenterol Hepatol. 2013;28(9):1469-75. doi:10.1111/jgh.12237.
  • Gierut JJ, Mathur PS, Bie W, Han J, Tyner AL. Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Ther. 2012;11(11):2311-20. doi:10.1158/1535-7163.MCT-12-0009.
  • Di A, Gao XP, Qian F, Kawamura T, Han J, Hecquet C, Ye RD, Vogel SM, Malik AB. The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nat Immunol. 2012;13(1):29-34. doi:10.1038/ni.2171.
  • Tang F, Chen Z, Ciszewski C, Setty M, Solus J, Tretiakova M, Ebert E, Han J, Lin A, Guandalini S, Groh V, Spies T, Green P, Jabri B. Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J Exp Med. 2009;206(3):707-19. doi:10.1084/jem.20071887.
  • Dose M, Sleckman BP, Han J, Bredemeyer AL, Bendelac A, Gounari F. Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc. Proc Natl Acad Sci U S A. 2009;106(21):8641-6. doi:10.1073/pnas.0812255106.
  • Onabajo OO, Seeley MK, Kale A, Qualmann B, Kessels M, Han J, Tan TH, Song W. Actin-binding protein 1 regulates B cell receptor-mediated antigen processing and presentation in response to B cell receptor activation. J Immunol. 2008;180(10):6685-95. doi:10.4049/jimmunol.180.10.6685.
  • Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, Lantz O, Bendelac A. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity. 2008;29(3):391-403. doi:10.1016/j.immuni.2008.07.011.
  • Shui JW, Boomer JS, Han J, Xu J, Dement GA, Zhou G, Tan TH. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses. Nat Immunol. 2007;8(1):84-91. doi:10.1038/ni1416.
  • Han J, Shui JW, Zhang X, Zheng B, Han S, Tan TH. HIP-55 is important for T-cell proliferation, cytokine production, and immune responses. Mol Cell Biol. 2005;25(16):6869-78. doi:10.1128/MCB.25.16.6869-6878.2005.
  • Zheng B, Marinova E, Han J, Tan TH, Han S. Cutting edge: gamma delta T cells provide help to B cells with altered clonotypes and are capable of inducing Ig gene hypermutation. J Immunol. 2003;171(10):4979-83.
  • Han J, Kori R, Shui JW, Chen YR, Yao Z, Tan TH. The SH3 domain-containing adaptor HIP-55 mediates c-Jun N-terminal kinase activation in T cell receptor signaling. J Biol Chem. 2003;278(52):52195-202. doi:10.1074/jbc.M305026200.
  • Chen YR, Han J, Kori R, Kong AN, Tan TH. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem. 2002;277(42):39334-42. doi:10.1074/jbc.M202070200.
  • Education

  • OtherPharmacy Practice Residency, , Rush University Medical Center, Chicago, IL
  • PharmD, , University of Illinois at Chicago, Chicago
  • PhD, , Baylor College of Medicine, Houston, TX
  • Licensures and Certifications

  • Board of Pharmaceutical Specialties, Board Certified Pharmacotherapy Specialist (BCPS), 2013
  • State of Illinois Dept. of Financial & Professional Regulation, Registered Pharmacist, 2012
  • Professional Memberships

  • American College of Clinical Pharmacy
  • Rho Chi Society